H2-Receptor Antagonists — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

7 Recruiting

2 Completed trials

2 Sponsors

18 Countries

Phase III

Phase I/II

Phase III: 8 Phase I/II: 1

Oversight events:

2 unexpected events across 2 trials

View oversight register →

Indications tested

Ductal adenocarcinoma of pancreas 1 Non-small cell lung cancer stage IIIB 1 Non-small cell lung cancer stage IIIA 1 Non-small cell lung cancer stage II 1 Ovarian epithelial cancer recurrent 1 Hormone receptor positive breast cancer 1 Ovarian cancer recurrent 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 7 Novartis Pharma AG 2

All trials

9 total

A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Phase III 14 countries Merck Sharp & Dohme LLC
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Phase III 16 countries Merck Sharp & Dohme LLC
A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting

2024-510635-21-00 Phase III 6 countries Novartis Pharma AG
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Phase III 13 countries Merck Sharp & Dohme LLC
Pembrolizumab With or Without Maintenance MK‑2870 in Metastatic Squamous NSCLC Recruiting

2023-510128-66-00 Phase III 10 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 alone or with other treatments to treat gastrointestinal cancers (MK-9999-02A) Recruiting

2023-508703-21-00 Phase I/II 2 countries Merck Sharp & Dohme LLC
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Phase III 15 countries Merck Sharp & Dohme LLC
A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended

2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC
A phase 3, randomized, double- blind, study of ianalumab (VAY736) versus placebo in addition to eltrombopag in primary immune thrombocytopen… Ended

2024-512890-28-00 Phase III 11 countries Novartis Pharma AG

Showing 1–9 of 9 trials

← All drugs A–Z